This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.
Prescribing Information for SARCLISA®▼(isatuximab) can be found via the Product Card at the bottom of the page.
Multiple myeloma is a blood cancer accounting for 2% of cancers in the United Kingdom.1
Despite available treatments, multiple myeloma remains an incurable malignancy and is associated with significant patient burden, with patients relapsing over time.2 As they relapse, patients can become refractory/resistant to treatments.3
Sanofi Oncology is committed to the management of patients with multiple myeloma.
SARCLISA® (isatuximab) is indicated:
In combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.
In combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.4
Relapsed Refractory Multiple Myeloma Product
- Cancer Research UK. Myeloma statistics. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma (last accessed September 2023)
- Myeloma UK. What is myeloma? Available at: https://www.myeloma.org.uk/understanding-myeloma/what-is-myeloma (last accessed September 2023)
- Kurtin SE (2013) Relapsed or Relapsed/Refractory Multiple Myeloma. Advancedpractitioner.com: Vol 4, No. 6, Suppl 1. Available at: https://www.advancedpractitioner.com/media/164110/005.pdf (last accessed September 2023).
- Sarclisa Summary of Product Characteristics (SmPC). Available at: https://www.medicines.org.uk/emc/ (last accessed September 2023).
Date of preparation: September 2023
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.